Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Feb 12, 2025
Deals
Antithrombotic comes back to Novartis via deal for Blackstone-backed Anthos
Pharma had held minority stake in 2019 spinout of mAb, now in Phase III for atrial fibrillation and cancer-associated thrombosis
BioCentury | Sep 5, 2023
Politics, Policy & Law
Novartis follows suit with IRA litigation
Company’s Entresto is among first cohort of drugs selected for price-setting under Inflation Reduction Act
BioCentury | Aug 30, 2023
Politics, Policy & Law
IRA drug list underscores challenges for industry
Selections underline difficulty in predicting how Inflation Reduction Act will be implemented
BioCentury | Aug 25, 2023
Product Development
Novo’s Wegovy notches second CV win, with a third readout due in 4Q
After statistically significant cardiovascular outcomes readout this month, Novo reports symptomatic relief in heart failure patients
BioCentury | Jul 20, 2022
Market Access
Novartis’ American ambitions
Can the Swiss pharma crack into the top five in the U.S. market, based on its current pipeline?
BioCentury | Apr 28, 2022
Finance
Biofourmis to grow data platform with General Atlantic-led $300M series D
Medtronic’s Omar Ishrak appointed chairman
BioCentury | Apr 26, 2022
Management Tracks
Novartis taps Bernstein’s Gal for new C-level strategy and growth position
Former analyst will ‘prioritize the portfolio’ as pharma sharpens focus on higher-value launches
BioCentury | Apr 4, 2022
Product Development
Novartis’ new page prioritizes ‘high-value’ multibillion dollar assets
Narasimhan’s restructuring reunites oncology with rest of pharma, creates new role of chief strategy & growth officer
BioCentury | Aug 31, 2021
Regulation
Turning biomarkers into surrogates, starting with the familiar
Mining decades of clinical practice, three fields are making surrogate endpoints out of common prognostic markers
BioCentury | Aug 30, 2021
Regulation
The promise and problems of expediting drug approvals
Overview of status of expedited approval pathways sets stage for BioCentury’s 29th Back to School
Items per page:
1 - 10 of 95